Engineering Anticytokine Antibodies for Immune Modulation
Copyright © 2024 by The American Association of Immunologists, Inc..
The delicate balance of immune homeostasis is regulated by the interactions between cytokines and their cognate cell surface signaling receptors. There is intensive interest in harnessing cytokines as drugs for diseases such as cancer and autoimmune disorders. However, the multifarious and often contradictory activities of cytokines, coupled with their short serum half-lives, limit clinical performance and result in dangerous toxicities. There is thus growing emphasis on manipulating natural cytokines to enhance their selectivity, safety, and durability through various strategies. One strategy that has gained traction in recent years is the development of anticytokine Abs that not only extend the circulation half-life of cytokines but also specifically bias their immune activities through multilayered molecular mechanisms. Although Abs are notorious for their antagonistic activities, this review focuses on anticytokine Abs that selectively agonize the activity of the target protein. This approach has potential to help realize the clinical promise of cytokine-based therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:212 |
|---|---|
| Enthalten in: |
Journal of immunology (Baltimore, Md. : 1950) - 212(2024), 2 vom: 15. Jan., Seite 225-234 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tomala, Jakub [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 13.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4049/jimmunol.2300467 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36656885X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36656885X | ||
| 003 | DE-627 | ||
| 005 | 20240213232725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.2300467 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1290.xml |
| 035 | |a (DE-627)NLM36656885X | ||
| 035 | |a (NLM)38166248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tomala, Jakub |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineering Anticytokine Antibodies for Immune Modulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 13.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 by The American Association of Immunologists, Inc. | ||
| 520 | |a The delicate balance of immune homeostasis is regulated by the interactions between cytokines and their cognate cell surface signaling receptors. There is intensive interest in harnessing cytokines as drugs for diseases such as cancer and autoimmune disorders. However, the multifarious and often contradictory activities of cytokines, coupled with their short serum half-lives, limit clinical performance and result in dangerous toxicities. There is thus growing emphasis on manipulating natural cytokines to enhance their selectivity, safety, and durability through various strategies. One strategy that has gained traction in recent years is the development of anticytokine Abs that not only extend the circulation half-life of cytokines but also specifically bias their immune activities through multilayered molecular mechanisms. Although Abs are notorious for their antagonistic activities, this review focuses on anticytokine Abs that selectively agonize the activity of the target protein. This approach has potential to help realize the clinical promise of cytokine-based therapies | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Cao, Shanelle D |e verfasserin |4 aut | |
| 700 | 1 | |a Spangler, Jamie B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology (Baltimore, Md. : 1950) |d 1945 |g 212(2024), 2 vom: 15. Jan., Seite 225-234 |w (DE-627)NLM000018554 |x 1550-6606 |7 nnns |
| 773 | 1 | 8 | |g volume:212 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:225-234 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4049/jimmunol.2300467 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 212 |j 2024 |e 2 |b 15 |c 01 |h 225-234 | ||